Skip to main content
News Icon

News categories: Publication

Alzheimer's Study published in Cell Reports

Alzheimer's disease: Inflammation triggers fatal cycle

University of Bonn study proves disastrous contribution of an ancient immune mechanism

An immune reaction in the brain seems to play a major role in the development of Alzheimer's disease. In a way, it "adds fuel to the fire" and apparently causes an inflammation that, in a sense, keeps kindling itself. The study has now been published in the journal Cell Reports. Alzheimer's disease is characterized by clumps of the protein Aß (amyloid beta), which form large plaques in the brain. Aß resembles molecules on the surface of some bacteria. Over many millions of years, organisms have therefore developed defense mechanisms against such structures. These mechanisms are genetically determined and therefore belong to the so-called innate immune system. They usually result in certain scavenger cells absorbing and digesting the molecule.

In the brain, the microglia cells take over this role. In doing so, however, they trigger a devastating process that appears to be largely responsible for the development of dementia. On contact with Aß, certain molecule complexes, the inflammasomes, become active in the microglia cells. They then resemble a wheel with enzymes on the outside. These can activate immune messengers and thereby trigger an inflammation by directing additional immune cells to the site of action.

"Sometimes the microglia cells perish during this process," explains Prof. Dr. Michael Heneka, head of a research group at the German Center for Neurodegenerative Diseases (DZNE) and director of the Department of Neurodegenerative Diseases and Gerontopsychiatry at the University Hospital Bonn. "Then they release activated inflammasomes into their environment, the ASC specks." Prof. Michael Heneka is a member of the Cluster of Excellence ImmunoSensation.


Publication

Lea L. Friker, Hannah Scheiblich, Inga V. Hochheiser, Rebecca Brinkschulte, Dietmar Riedel, Eicke Latz, Matthias Geyer and Michael T. Heneka: Amyloid Clustering around ASC Fibrils Boosts Its Toxicity in Microglia; Cell Reports; DOI: 10.1016/j.celrep.2020.02.025

Contact

Prof. Dr. Michael Heneka

Director of the Department of Neurodegenerative Diseases and Gerontopsychiatry

University Hospital Bonn

German Center for Neurodegenerative Diseases (DZNE)

Tel. +49-(0)228-28713091

E-mail: michael.heneka@dzne.de

Related news

Bunte Spirale

News categories: Publication

When the map needs an update

Every time we move through a familiar environment, the hippocampus consults an internal map, a detailed spatial representation that is built up through repeated experience. But what happens when something unexpected occurs on a well-known route? Researchers at the UKB and the University of Bonn were able to demonstrate in a mouse model that the brain does not redraw its maps from scratch. Instead, it annotates them: preserving the underlying spatial layout while overlaying new information on top of the existing map. Their findings have now been published in the journal PNAS.
View entry
Dr. Clivia Lisowski und Prof. Christian Kurts

News categories: Publication

Immune cells in the liver help pigeons navigate

How do pigeons find their way home safely over distances of many kilometers? A research team from the University Hospital Bonn (UKB), the University of Bonn, the University of Duisburg-Essen, and the Max Planck Institute for Behavioral Biology has now discovered a previously unknown mechanism: specific immune cells in the liver may help the birds detect the Earth’s magnetic field. The findings have now been published in the journal Science.
View entry
News Icon

News categories: Publication

Twin Lancet Publications Highlight Promising New Approach for Lupus Treatment

A team of international researchers, including ImmunoSensation³ member Prof. Jörg Wenzel, reports promising phase 2 results for enpatoran, a first-in-class oral TLR7/8 inhibitor, in patients with cutaneous and systemic lupus erythematosus (CLE/SLE). In the WILLOW trial, enpatoran significantly improved skin disease activity in a dose-dependent manner and showed favourable safety outcomes. In systemic SLE, treatment also reduced global disease activity and rapidly suppressed the type I interferon gene signature. The twin studies were published in The Lancet and The Lancet Rheumatology.
View entry

Back to the news overview